The independent medical news service

Supplementing androgen deprivation therapy with 2 years of an abiraterone acetate-based regimen significantly boosts the survival of men with high-risk nonmetastatic prostate cancer, show STAMPEDE results.

The addition of abiraterone acetate to standard therapy with docetaxel plus androgen deprivation therapy significantly improves the overall survival of patients with de novo metastatic castration-sensitive prostate cancer, report the PEACE-1 investigators.

The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

Phase 2 study data show that the PARP inhibitor talazoparib has antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer bearing DNA damage response alterations in genes associated with homologous recombination repair.